Loading stock data…
TBPH
$16.79+0.05 (+0.30%)
Market ClosedLast close May 1
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Theravance Biopharma, Inc. in the Healthcare sector is trading at $16.79. The stock is currently 20% below its 52-week high of $21.03, remaining 5.3% above its 200-day moving average. Technical signals show neutral RSI of 56 and bullish MACD crossover, explaining why TBPH maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 56) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$16.79
Potential Upside
212.5%
Whystock Fair Value$52.47
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus5 analysts
Buy
Mean target$17.20+2.4%
Range$15.00 – $21.00
Fundamentals
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary dise...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$853.24M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
8.04
Beta
Defensive asset. Lower volatility than the S&P 500.
0.17
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
35.69%
Volume
Today's trading volume
287,546
Recent News
CORT Q1 Earnings Match Estimates, Revenues Miss, 2026 Outlook Raised
Corcept Q1 loss meets estimates, while revenues miss. The company boosts 2026 outlook as new drug Lifyorli and rising Korlym demand reshape growth trajectory.
Laughing Water Capital’s New Position: Theravance Biopharma (TBPH)
Laughing Water Capital, an investment management company, released its first-quarter 2026 investor letter. A copy of the letter can be downloaded here. The Class A investment in Laughing Water Capital returned approximately -4.5% net of all fees and expenses in the first quarter of 2026. The SP500TR and R2000 returned -4.3% and 0.9% respectively, during the […]
B. Riley Lifts PT on Theravance Biopharma (TBPH) to $17 From $14
Theravance Biopharma, Inc. (NASDAQ:TBPH) is one of the most undervalued biotech stocks to buy right now. B. Riley lifted the price target on Theravance Biopharma, Inc. (NASDAQ:TBPH) to $17 from $14 on April 7, reiterating a Neutral rating on the shares. The firm told investors that the final generic settlement with MannKind Corporation locks exclusivity through […]
Theravance Stock Declines Around 17% in Three Months: Here's Why
TBPH shares sink in three months after its lead drug fails a late-stage study, forcing a pipeline overhaul and raising uncertainty over its future direction.
Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics
Small drug stocks like Indivior gain traction as biotech recovery strengthens, fueled by innovation, M&A activity, and promising pipeline developments.